Insights into subtype selectivity of opioid agonists by ligand-based and structure-based methods

To probe the selective mechanism of agonists binding to three opioid receptor subtypes, ligand-based and receptor-based methods were implemented together and subtype characteristics of opioid agonists were clearly described. Three pharmacophore models of opioid agonists were generated by the Catalyst/HypoGen program. The best pharmacophore models for μ, δ and κ agonists contained four, five and five features, respectively. Meanwhile, the three-dimensional structures of three receptor subtypes were modeled on the basis of the crystal structure of β2-adrenergic receptor, and molecular docking was conducted further. According to these pharmacophore models and docking results, the similarities and differences among agonists of three subtypes were identified. μ or δ agonists, for example, could form one hydrogen bond separately with Tyr129 and Tyr150 at TMIII, whereas κ ones formed a π-π interaction in that place. These findings may be crucial for the development of novel selective analgesic drugs.

[1]  Y. Shimohigashi,et al.  Ligand recognition in mu opioid receptor: experimentally based modeling of mu opioid receptor binding sites and their testing by ligand docking. , 1996, Bioorganic & medicinal chemistry.

[2]  Jian Li,et al.  Rationale, design, and synthesis of novel phenyl imidazoles as opioid receptor agonists for gastrointestinal disorders. , 2004, Journal of medicinal chemistry.

[3]  Jiali Gao,et al.  Homology Modeling and Molecular Dynamics Simulations of the Mu Opioid Receptor in a Membrane–Aqueous System , 2005, Chembiochem : a European journal of chemical biology.

[4]  Mahalaxmi Aburi,et al.  Modeling and simulation of the human δ opioid receptor , 2004 .

[5]  T. Graczyk,et al.  Novel malonamide derivatives as potent κ opioid receptor agonists , 2007 .

[6]  C. Dardonville,et al.  Fentanyl derivatives bearing aliphatic alkaneguanidinium moieties: a new series of hybrid molecules with significant binding affinity for mu-opioid receptors and I2-imidazoline binding sites. , 2004, Bioorganic & medicinal chemistry letters.

[7]  Xufeng Sun,et al.  Syntheses and opioid receptor binding affinities of 8-amino-2,6-methano-3-benzazocines. , 2003, Journal of medicinal chemistry.

[8]  J. Cassel,et al.  Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity. , 1999, The Journal of pharmacology and experimental therapeutics.

[9]  Yun Tang,et al.  Molecular modeling and 3D-QSAR studies of indolomorphinan derivatives as kappa opioid antagonists. , 2006, Bioorganic & medicinal chemistry.

[10]  K. Rice,et al.  delta Opioid affinity and selectivity of 4-hydroxy-3-methoxyindolomorphinan analogues related to naltrindole. , 1999, Journal of medicinal chemistry.

[11]  Qiang Zhang,et al.  3D-QSAR comparative molecular field analysis on delta opioid receptor agonist SNC80 and its analogs. , 2005, Journal of molecular graphics & modelling.

[12]  W. Greenlee,et al.  Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. , 2007, Bioorganic & medicinal chemistry letters.

[13]  P. Pitis,et al.  N,N-dialkyl-4-[(8-azabicyclo[3.2.1]-oct-3-ylidene)phenylmethyl]benzamides, potent, selective delta opioid agonists. , 2004, Bioorganic & medicinal chemistry letters.

[14]  R. Shank,et al.  Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. , 1995, The Journal of pharmacology and experimental therapeutics.

[15]  J. Eisenach,et al.  Pharmacology of opioid and nonopioid analgesics in chronic pain states. , 2001, The Journal of pharmacology and experimental therapeutics.

[16]  W. Fratta,et al.  N-3(9)-arylpropenyl-N-9(3)-propionyl-3,9-diazabicyclo[3.3.1]nonanes as mu-opioid receptor agonists. Effects on mu-affinity of arylalkenyl chain modifications. , 2002, Bioorganic & medicinal chemistry.

[17]  Thierry Langer,et al.  Combining Ethnopharmacology and Virtual Screening for Lead Structure Discovery: COX-Inhibitors as Application Example , 2004, J. Chem. Inf. Model..

[18]  A. Lomize,et al.  Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints. , 1998, Biophysical journal.

[19]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[20]  S. Kato,et al.  Location of Regions of the Opioid Receptor Involved in Selective Agonist Binding (*) , 1995, The Journal of Biological Chemistry.

[21]  Yun Tang,et al.  Corrigendum to “Molecular modeling and 3D-QSAR studies of indolomorphinan derivatives as kappa opioid antagonists” [Bioorg. Med. Chem. 14 (2006) 601–610] , 2006 .

[22]  P. Roy,et al.  On Some Aspects of Variable Selection for Partial Least Squares Regression Models , 2008 .

[23]  S. Villa,et al.  Synthesis of 3,6-diazabicyclo[3.1.1]heptanes as novel ligands for the opioid receptors. , 2006, Bioorganic & medicinal chemistry.

[24]  C. Dardonville,et al.  Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites. , 2006, Bioorganic & medicinal chemistry.

[25]  G. Chang,et al.  An internal-coordinate Monte Carlo method for searching conformational space , 1989 .

[26]  A. Beaudet,et al.  Up-regulation and trafficking of δ opioid receptor in a model of chronic inflammation: implications for pain control , 2003, Pain.

[27]  B. Wünsch,et al.  Methylated analogues of methyl (R)-4-(3,4-dichlorophenylacetyl)- 3-(pyrrolidin-1-ylmethyl)piperazine-1-carboxylate (GR-89,696) as highly potent kappa-receptor agonists: stereoselective synthesis, opioid-receptor affinity, receptor selectivity, and functional studies. , 2001, Journal of medicinal chemistry.

[28]  C. George,et al.  Probes for Narcotic Receptor Mediated Phenomena , 2003 .

[29]  U. Holzgrabe,et al.  Mechanism of action of the diazabicyclononanone-type kappa-agonists. , 2003, Journal of medicinal chemistry.

[30]  Irina D Pogozheva,et al.  Refinement of a homology model of the mu-opioid receptor using distance constraints from intrinsic and engineered zinc-binding sites. , 2004, Biochemistry.

[31]  M. Spetea,et al.  Synthesis and Biological Evaluation of 14‐Alkoxymorphinans. Part 19 , 2003 .

[32]  R. Stevens,et al.  High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.

[33]  T. Meert,et al.  4-Phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives, a novel class of selective δ-opioid agonists , 2006 .

[34]  R. Stevens,et al.  GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function , 2007, Science.

[35]  W. Greenlee,et al.  Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. , 2007, Bioorganic & medicinal chemistry letters.

[36]  Simona Collina,et al.  Synthesis, biological evaluation, and receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as kappa-opioid receptor agonists endowed with antinociceptive and antiamnesic activity. , 2003, Journal of medicinal chemistry.

[37]  G. Uhl,et al.  -mu opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. , 1994, The Journal of biological chemistry.

[38]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[39]  M. Aceto,et al.  Synthesis and biological evaluation of 14-alkoxymorphinans. 20. 14-phenylpropoxymetopon: an extremely powerful analgesic. , 2003, Journal of medicinal chemistry.

[40]  J. Deschamps,et al.  Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series. , 2007, Journal of medicinal chemistry.

[41]  Marta Filizola,et al.  Differentiation of δ, μ, and κ opioid receptor agonists based on pharmacophore development and computed physicochemical properties , 2001, J. Comput. Aided Mol. Des..

[42]  G. Pasternak Insights into mu opioid pharmacology the role of mu opioid receptor subtypes. , 2001, Life sciences.

[43]  Weiliang Zhu,et al.  Neuraminidase pharmacophore model derived from diverse classes of inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[44]  L. Cortes-Burgos,et al.  Arylacetamides as peripherally restricted kappa opioid receptor agonists. , 2000, Bioorganic & Medicinal Chemistry Letters.

[45]  Xiaodong Zhang,et al.  Synthesis and biological evaluation of some 6-arylamidomorphines as analogues of morphine-6-glucuronide. , 2004, Bioorganic & medicinal chemistry.

[46]  Michael Koblish,et al.  Novel phenylamino acetamide derivatives as potent and selective κ opioid receptor agonists , 2006 .

[47]  Sui-Po Zhang,et al.  Identification of potent phenyl imidazoles as opioid receptor agonists. , 2006, Bioorganic & medicinal chemistry letters.

[48]  David M. Ferguson,et al.  A combined ligand-based and target-based drug design approach for G-protein coupled receptors: application to salvinorin A, a selective kappa opioid receptor agonist , 2006, J. Comput. Aided Mol. Des..

[49]  Cécile Béguin,et al.  Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2). , 2005, Bioorganic & medicinal chemistry letters.

[50]  Steven L. Teig,et al.  Chemical Function Queries for 3D Database Search , 1994, J. Chem. Inf. Comput. Sci..

[51]  E Novellino,et al.  Modeling of kappa-opioid receptor/agonists interactions using pharmacophore-based and docking simulations. , 2000, Journal of medicinal chemistry.

[52]  Judith L. Flippen-Anderson,et al.  Diaryldimethylpiperazine ligands with μ- and δ-opioid receptor affinity: Synthesis of (+)-4-[(αR)-α-(4-allyl-(2S, 5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl]- N-ethyl-N-phenylbenzamide and (-)-4-[(αR)-α-(2S, 5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl]-N-ethyl-N -phenylbenzamide , 2003 .

[53]  Michael Koblish,et al.  Synthesis and evaluation of novel peripherally restricted κ-opioid receptor agonists , 2005 .

[54]  P. Pitis,et al.  Parallel methods for the preparation and SAR exploration of N-ethyl-4-[(8-alkyl-8-aza-bicyclo[3.2.1]oct-3-ylidene)-aryl-methyl]-benzamides, powerful mu and delta opioid agonists. , 2004, Bioorganic & medicinal chemistry letters.

[55]  J. Spudich,et al.  Crystal Structure of Sensory Rhodopsin II at 2.4 Angstroms: Insights into Color Tuning and Transducer Interaction , 2001, Science.

[56]  Xufeng Sun,et al.  Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 2: 8-formamidocyclazocine analogues. , 2003, Bioorganic & Medicinal Chemistry Letters.

[57]  D. Pagé,et al.  New scaffolds in the development of mu opioid-receptor ligands. , 2003, Bioorganic & medicinal chemistry letters.

[58]  E. Meng,et al.  Rhodopsin Sees the Light , 2000, Science.

[59]  T. Steckler,et al.  4-Phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives as non-peptidic selective delta-opioid agonists with potential anxiolytic/antidepressant properties. Part 2. , 2007, Bioorganic & medicinal chemistry letters.

[60]  G. Pasternak,et al.  Ontogeny of opioid pharmacology and receptors: high and low affinity site differences. , 1981, European journal of pharmacology.

[61]  S C Basak,et al.  A quantitative structure-activity relationship study of N-alkylnorketobemidones and triazinones using structural information content. , 1982, Arzneimittel-Forschung.

[62]  T. Hökfelt,et al.  Activation of Delta Opioid Receptors Induces Receptor Insertion and Neuropeptide Secretion , 2003, Neuron.

[63]  R. Dolle,et al.  Peripherally restricted opioid agonists as novel analgesic agents. , 2004, Current pharmaceutical design.

[64]  John P. Overington,et al.  Derivation of rules for comparative protein modeling from a database of protein structure alignments , 1994, Protein science : a publication of the Protein Society.

[65]  D. Tulshian,et al.  Synthesis and structure-activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands. , 2007, Bioorganic & medicinal chemistry letters.

[66]  D. L. Larson,et al.  Conformational analysis and automated receptor docking of selective arylacetamide-based kappa-opioid agonists. , 1998, Journal of medicinal chemistry.

[67]  G. Chang,et al.  Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics , 1990 .

[68]  Yun Tang,et al.  QSAR study of 4-phenylpiperidine derivatives as mu opioid agonists by neural network method. , 2006, European journal of medicinal chemistry.

[69]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[70]  T. Graczyk,et al.  Potent and highly selective kappa opioid receptor agonists incorporating chroman- and 2,3-dihydrobenzofuran-based constraints. , 2005, Bioorganic & medicinal chemistry letters.

[71]  Joshua F. Nitsche,et al.  Retention of Supraspinal Delta-like Analgesia and Loss of Morphine Tolerance in δ Opioid Receptor Knockout Mice , 1999, Neuron.

[72]  S. Collina,et al.  Enantiomers of 2-[(Acylamino)ethyl]-1,4-benzodiazepines, potent ligands of kappa-opioid receptor: chiral chromatographic resolution, configurational assignment and biological activity. , 2001, Chirality.

[73]  M. Aceto,et al.  Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships. , 2003, Journal of medicinal chemistry.

[74]  M. Spetea,et al.  Synthesis and biological evaluation of 14-alkoxymorphinans. 22.(1) Influence of the 14-alkoxy group and the substitution in position 5 in 14-alkoxymorphinan-6-ones on in vitro and in vivo activities. , 2005, Journal of medicinal chemistry.

[75]  Qiong Xie,et al.  3D–QSAR studies of orvinol analogs as κ-opioid agonists , 2006 .